Last reviewed · How we verify
COS with GnRH antagonists and HP-HMG
This protocol combines controlled ovarian stimulation (COS) with GnRH antagonists to suppress premature luteinizing hormone surge and HP-HMG (highly purified human menopausal gonadotropin) to stimulate multiple follicle development for assisted reproductive technology.
This protocol combines controlled ovarian stimulation (COS) with GnRH antagonists to suppress premature luteinizing hormone surge and HP-HMG (highly purified human menopausal gonadotropin) to stimulate multiple follicle development for assisted reproductive technology. Used for Infertility treatment via controlled ovarian stimulation for in vitro fertilization (IVF), Assisted reproductive technology requiring multiple oocyte retrieval.
At a glance
| Generic name | COS with GnRH antagonists and HP-HMG |
|---|---|
| Also known as | GnRH antagonists and HP-HMG |
| Sponsor | Instituto Valenciano de Infertilidad, IVI VALENCIA |
| Drug class | Gonadotropin protocol / Assisted reproductive technology regimen |
| Target | GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Infertility |
| Phase | FDA-approved |
Mechanism of action
GnRH antagonists block gonadotropin-releasing hormone receptors to prevent the natural LH surge that would trigger premature ovulation during fertility treatment. Simultaneously, HP-HMG provides exogenous FSH and LH to promote controlled growth of multiple ovarian follicles. This combination allows precise timing of oocyte retrieval for in vitro fertilization or other assisted reproductive procedures.
Approved indications
- Infertility treatment via controlled ovarian stimulation for in vitro fertilization (IVF)
- Assisted reproductive technology requiring multiple oocyte retrieval
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Abdominal bloating and discomfort
- Headache
- Injection site reactions
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: